315 related articles for article (PubMed ID: 34094958)
1. Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma.
Li S
Front Oncol; 2021; 11():664853. PubMed ID: 34094958
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.
Shen G; Zheng F; Ren D; Du F; Dong Q; Wang Z; Zhao F; Ahmad R; Zhao J
J Hematol Oncol; 2018 Sep; 11(1):120. PubMed ID: 30231931
[TBL] [Abstract][Full Text] [Related]
3. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib as a molecular targeted therapy for tumors.
Gao Y; Liu P; Shi R
Oncol Lett; 2020 Aug; 20(2):1001-1014. PubMed ID: 32724339
[TBL] [Abstract][Full Text] [Related]
5. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study.
Wu J; Li C; Liu B; Liu Q; Liu D; Wang Z; Wang X; Jia W; Tian X; Hao C
Ann Transl Med; 2023 Mar; 11(5):212. PubMed ID: 37007540
[TBL] [Abstract][Full Text] [Related]
7. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F
Thorac Cancer; 2019 Mar; 10(3):551-556. PubMed ID: 30666799
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer.
Zhong RB; Xu JL; Lou YQ; Chu TQ; Zhong H; Han BH
Ann Palliat Med; 2020 Jul; 9(4):1681-1687. PubMed ID: 32575999
[TBL] [Abstract][Full Text] [Related]
9. Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib.
Li S; Wang H
Drug Des Devel Ther; 2023; 17():3429-3437. PubMed ID: 38024530
[TBL] [Abstract][Full Text] [Related]
10. Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature.
Zhang Y; He W; Zhan K; Zhang L; Cao H; Xu R
Front Oncol; 2023; 13():1153233. PubMed ID: 37260970
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment.
Wang J; Zhao Y; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Yu H; Zhao Y; Chen W; Luo Y; Wang X; Nan K; Jin F; Dong J; Li B; Liu Z; Han B; Li K
Cancer Biol Med; 2018 Nov; 15(4):443-451. PubMed ID: 30766754
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
Ma J; Song Y; Shou J; Bai Y; Li H; Xie X; Luo H; Ren X; Liu J; Ye D; Bai X; Fu C; Qin S; Wang J; Zhou AP
Front Oncol; 2020; 10():664. PubMed ID: 32457838
[No Abstract] [Full Text] [Related]
13. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
Sun Y; Niu W; Du F; Du C; Li S; Wang J; Li L; Wang F; Hao Y; Li C; Chi Y
J Hematol Oncol; 2016 Oct; 9(1):105. PubMed ID: 27716285
[TBL] [Abstract][Full Text] [Related]
14. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
15. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
Yang X; Xiang M; Geng L; Wen Y; Du X
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3849-3853. PubMed ID: 31870132
[TBL] [Abstract][Full Text] [Related]
18. [Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma].
Song Y; Yihebali C; Yang L; Cui CX; Zhang W; Sun YK; Du CX; Zhou AP; Wang JW
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):765-770. PubMed ID: 32988160
[No Abstract] [Full Text] [Related]
19. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
[TBL] [Abstract][Full Text] [Related]
20. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
